Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Insider Sells $91,190.75 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Douglas Kerr sold 3,745 shares of the firm’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $24.35, for a total value of $91,190.75. Following the transaction, the insider owned 163,854 shares of the company’s stock, valued at $3,989,844.90. The trade was a 2.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Douglas Kerr also recently made the following trade(s):

• On Tuesday, September 8th, Douglas Kerr sold 1,290 shares of Dyne Therapeutics stock. The stock was sold at an average price of $18.88, for a total transaction of $24,355.20.

Dyne Therapeutics Stock Performance

Shares of Dyne Therapeutics stock opened at $18.42 on Friday. Dyne Therapeutics, Inc. has a 1 year low of $11.92 and a 1 year high of $27.31. The firm’s 50-day moving average is $24.68 and its 200 day moving average is $20.54. The stock has a market cap of $3.44 billion, a price-to-earnings ratio of -5.53 and a beta of 1.08. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). Sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

DYN has been the subject of several analyst reports. Evercore set a $33.00 price target on shares of Dyne Therapeutics in a research report on Friday, May 15th. Morgan Stanley lowered their price objective on Dyne Therapeutics from $45.00 to $36.00 and set an “overweight” rating on the stock in a research report on Wednesday. Raymond James Financial reiterated a “strong-buy” rating and set a $37.00 target price on shares of Dyne Therapeutics in a research note on Tuesday. Cantor Fitzgerald initiated coverage on Dyne Therapeutics in a report on Thursday, July 23rd. They issued an “overweight” rating for the company. Finally, HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Monday, August 17th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Dyne Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $32.17.

Institutional Trading of Dyne Therapeutics

A number of large investors have recently made changes to their positions in DYN. Creative Planning raised its stake in shares of Dyne Therapeutics by 6.8% in the third quarter. Creative Planning now owns 15,527 shares of the company’s stock worth $196,000 after buying an additional 986 shares during the period. Hilton Head Capital Partners LLC purchased a new position in shares of Dyne Therapeutics during the 1st quarter valued at about $26,000. Caxton Associates LLP grew its stake in shares of Dyne Therapeutics by 10.9% during the 2nd quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock valued at $158,000 after acquiring an additional 1,627 shares during the period. Steward Partners Investment Advisory LLC grew its stake in shares of Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after acquiring an additional 2,465 shares during the period. Finally, Strs Ohio purchased a new stake in Dyne Therapeutics in the 4th quarter worth approximately $51,000. 96.68% of the stock is currently owned by institutional investors.

Trending Headlines about Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Morgan Stanley reaffirmed its Buy rating on Dyne, signaling continued confidence in the company’s pipeline and long-term outlook. Morgan Stanley reaffirmed Buy rating
• Positive Sentiment: RBC maintained an Outperform rating, saying Dyne’s DM1 approach remains differentiated, although it reduced its price target from $35 to $30. Investors are also awaiting additional six- and 12-month data for DYNE-101 and topline results from the fully enrolled ACHIEVE expansion cohort, expected in the first quarter of 2027. RBC assessment of Dyne’s DM1 approach
• Neutral Sentiment: Unusually heavy call-option activity was reported, with roughly 20,532 calls traded versus average daily volume of about 464. The activity may indicate speculative expectations for a rebound or clinical-data catalyst, but it does not establish improving fundamentals. Unusually large options trading in DYN
• Neutral Sentiment: Reported short interest was zero shares, implying no meaningful short-selling position or days-to-cover exposure based on the figures provided. This is unlikely to be a major near-term trading catalyst.
• Negative Sentiment: JPMorgan downgraded DYN from Neutral to Underweight and cut its price target from $17 to $10. The move followed a rival DM1 therapy’s Phase 3 failure, which raised concerns about clinical and commercial risks across the disease class. JPMorgan downgrade following Novartis setback
• Negative Sentiment: An insider sold 900 shares for approximately $21,915, reportedly to cover tax withholding tied to vested equity awards. The sale was small relative to the insider’s remaining holdings, limiting its fundamental significance, but it may add modestly to cautious sentiment. Dyne insider stock sale

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.